ClinicalTrials.gg
RecruitingNCT04077528RAMSESUpdated Jan 18, 2024

Research on Severe Asthma

An observational study in Adult Severe Asthma Patients Treated in France, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-18.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Started Sep 2019; still recruiting 7 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Asthma by Assistance Publique - Hôpitaux de Paris — 5 open to participants now, 6 under way, none of them phase 3. Asthma · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
Largest of 18
2,000 · median 113
Started
2019
with 2 others
Observational
18 of 31
3 open now
Registered
16th of 31
by date

Among the 31 studies in Asthma by Assistance Publique - Hôpitaux de Paris, this one has the largest planned enrollment of the 18 observational ones that give a count, is one of 3 that started in 2019, is one of 18 observational ones, and was the 16th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

5 of the 31 studies in Asthma by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Asthma by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

The French Society for Respiratory diseases (SPLF), through its Asthma and Allergy working group (G2A), wishes to set up a national cohort of severe asthma patients to describe this population and the use of step 4 and 5 treatment. This study also meets the demand for post - registration studies required by the Health Authorities for biotherapies and bronchial thermoplasty.

Other European or international cohorts of asthmatic patients exist and RAMSES could contribute to data sharing initiatives.

Read the detailed description

Severe asthma is defined by poorly controlled disease despite treatment with high doses of inhaled corticosteroids, in combination with at least a long acting beta agonist, after optimal management for at least 6 months by an asthma specialist. The diagnosis of severe asthma can only be made after a rigorous evaluation of 6 to 12 months, including the review of diagnosis and treatment, by a pulmonologist, to distinguish difficult asthma from severe asthma.

Severe asthma accounts for 3.5% to 5% of all asthma patients, a population estimated at 150 000 patients in France. This disease is responsible for significant health costs related to asthma treatments, comorbidities, hospitalizations and sick days. The management of severe asthma is complex, multidisciplinary and includes drug treatment, but also the management of side effects of treatment, including oral corticosteroid therapy, and comorbidities of asthma.

Until 2018, omalizumab,systemic continuous oral corticosteroid therapy or inclusion in a therapeutic trial were the ony possibilities offered to severe asthmatic patients beyond the usually recommended and optimized management. In 2018, mepolizumab and reslizumab have been marketed in France, then benralizumab in 2019. They will probably be followed by dupilumab and bronchial thermoplasty. New initiatives to change the history of the disease are also proposed such as specific immunotherapy or long-term use of macrolides. Respiratory rehabilitation is also part of the treatments to be evaluated in some groups of patients.

The description of the use of these treatments, as well as the evaluation of their effectiveness and tolerance in real life conditions is essential. Indeed, their use outside clinical trials raises a number of issues such as the optimal duration of treatment, the maintenance of efficacy over extended periods, the risk and the time to relapse when the treatment is stopped, the possibility to switch from one biotherapy to another in case of insufficient clinical response or to associate them which may prove to be an effective strategy in patients eligible for two biotherapies (allergic and eosinophilic patients).

The cost of these treatments is high. The pharmaco-economic evaluation of severe asthma and its management is another important element. For example, no economic evaluation of the use of omalizumab is currently available in France.

Lastly, the organization of a care network dedicated to severe asthma is being launched in France (severe asthma centers ), on the model of European countries, in order to improve the diagnosis and management of these patients and to reduce the burden of comorbidities of asthma and steroids side effects.It is therefore essential to set up a clinical research structure that will make it possible to obtain clinical data on this population of severe asthma patients and to evaluate all medical practices in real life conditions.

03

Conditions studied

  • Adult Severe Asthma Patients Treated in France

Keywords

  • Severe asthma
  • Adult
  • Respiratory disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult severe asthma patients treated in France

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with severe asthma : Meeting the definition of ATS-ERS: which requires a combination of high dose CSI and B2LDA.

Or receiving level 5 support (initiating treatment or already treated) :

  • Long-term oral (> 6 months in the year prior to inclusion)
  • And / or monoclonal antibody
  • And / or bronchial thermoplasty
  • And / or other complex costs corresponding to the level 5 treatments

    • Consultant or hospitalized in one of the centers participating in RAMSES study

Exclusion criteria

Exclusion Criteria:

  • Patient does not accept the recording of his data in the cohort
  • Patient not benefiting from health insurance coverage
  • Patient under curatorship or tutorship
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Number of patients receiving asthma treatment

    Severe asthma medication (high dose inhaled corticosteroids / B2LDA, Anti IgE antibody, Anti IL5 antibody, daily oral steroids...); Other asthma medications (long acting anticholinergics, montelukast, theophylline, inhaled corticoids); bronchial thermoplasty.

    Time frame: Previous treatment, collected at baseline

  2. Dose of severe asthma treatments

    Severe asthma medication (high dose inhaled corticosteroids / B2LDA, Anti IgE antibody, Anti IL5 antibody, daily oral steroids...)

    Time frame: At baseline

  3. Duration of asthma treatments

    Severe asthma medication (high dose inhaled corticosteroids / B2LDA, Anti IgE antibody, Anti IL5 antibody, daily oral steroids...); Other asthma medications (long acting anticholinergics, montelukast, theophylline, inhaled corticoids); bronchial thermoplasty.

    Time frame: Previous treatment, collected at baseline

  4. Other medications

    Number of patients receiving antidiabetics, Number of patients receiving antidepressants, Number of patients receiving anti-osteoporotic drugs, Number of patients receiving cardiovascular drugs.

    Time frame: At baseline

  5. Asthma-related comorbidities

    Prevalence of asthma related comorbidities such as chronic rhinosinusitis, nasal polyps, gastroesophageal reflux, obesity, obstructive sleep apnea respiratory infections, ...

    Time frame: At baseline

  6. Non-respiratory comorbidities

    Prevalence of non-respiratory comorbidities such as osteoporosis, diabetes , cardiovascular diseases...

    Time frame: At baseline

  7. Asthma control test (ACT)

    Patient-reported asthma symptoms and control will be collected via the ACT questionnaire; a 5 items, self-administered survey that is designed to help the patient describe their asthma and how it affects their daily activities. ACT questionnaire is a 5-point scale (for symptoms and activities: 1=all the time to 5= not at all; for asthma control rating: 1=not controlled at all to 5=completely controlled). Asthma is controlled when the total score is \>20.

    Time frame: 12 previous months, collected at baseline

  8. Asthma exacerbations

    Number of systemic corticosteroids (SC) courses

    Time frame: 12 previous months, collected at baseline

  9. Forced Expiratory Volume in 1 second (FEV1)

    Mean FEV1, expressed in ml.

    Time frame: 12 previous months, collected at baseline

  10. Number of patients with at least 1 sick leaves due to asthma

    Patient-reported sick leaves.

    Time frame: 12 previous months, collected at baseline

  11. Number of sick leaves due to asthma

    Patient-reported sick leaves.

    Time frame: 12 previous months, collected at baseline

  12. Number of patients with long term disease status for asthma

    Time frame: At baseline

  13. Intensive care unit hospitalization due to asthma exacerbation

    At least one intensive care unit hospitalization for asthma

    Time frame: During life, collected at baseline

Secondary outcomes

  1. Number of unscheduled healthcare visits or hospitalization

    Inpatient hospitalizations due to asthma including intensive care unit, inpatient hospitalization for other reasons, emergency department visits and unscheduled ambulatory visits

    Time frame: At 6 months

  2. Number of patients with unscheduled healthcare visits or hospitalization

    Inpatient hospitalizations due to asthma including intensive care unit, inpatient hospitalization for other reasons, emergency department visits and unscheduled ambulatory visits

    Time frame: At 6 months

  3. Number of unscheduled healthcare visits or hospitalization

    Inpatient hospitalizations due to asthma including intensive care unit, inpatient hospitalization for other reasons, emergency department visits and unscheduled ambulatory visits

    Time frame: At 12 months

  4. Number of patients with unscheduled healthcare visits or hospitalization

    Inpatient hospitalizations due to asthma including intensive care unit, inpatient hospitalization for other reasons, emergency department visits and unscheduled ambulatory visits

    Time frame: At 12 months

  5. Number of unscheduled healthcare visits or hospitalization

    Inpatient hospitalizations due to asthma including intensive care unit, inpatient hospitalization for other reasons, emergency department visits and unscheduled ambulatory visits

    Time frame: At 24 months

  6. Number of patients with unscheduled healthcare visits or hospitalization

    Inpatient hospitalizations due to asthma including intensive care unit, inpatient hospitalization for other reasons, emergency department visits and unscheduled ambulatory visits

    Time frame: At 24 months

  7. Number of unscheduled healthcare visits or hospitalization

    Inpatient hospitalizations due to asthma including intensive care unit, inpatient hospitalization for other reasons, emergency department visits and unscheduled ambulatory visits

    Time frame: At 36 months

  8. Number of patients with unscheduled healthcare visits or hospitalization

    Inpatient hospitalizations due to asthma including intensive care unit, inpatient hospitalization for other reasons, emergency department visits and unscheduled ambulatory visits

    Time frame: At 36 months

  9. Number of unscheduled healthcare visits or hospitalization

    Inpatient hospitalizations due to asthma including intensive care unit, inpatient hospitalization for other reasons, emergency department visits and unscheduled ambulatory visits

    Time frame: At 60 months

  10. Number of patients with unscheduled healthcare visits or hospitalization

    Inpatient hospitalizations due to asthma including intensive care unit, inpatient hospitalization for other reasons, emergency department visits and unscheduled ambulatory visits

    Time frame: At 60 months

  11. Daily dose of corticosteroids

    Inhaled corticosteroids, oral corticosteroids (SC) in long term users

    Time frame: At 6 months

  12. Daily dose of corticosteroids

    Inhaled corticosteroids, oral corticosteroids (SC) in long term users

    Time frame: At 12 months

  13. Daily dose of corticosteroids

    Inhaled corticosteroids, oral corticosteroids (SC) in long term users

    Time frame: At 24 months

  14. Daily dose of corticosteroids

    Inhaled corticosteroids, oral corticosteroids (SC) in long term users

    Time frame: At 36 months

  15. Daily dose of corticosteroids

    Inhaled corticosteroids, oral corticosteroids (SC) in long term users

    Time frame: At 60 months

  16. Number of patients with at least 1 other asthma medication

    Long acting beta 2 agonists, long acting anticholinergics, montelukast, macrolides, Anti IgE monoclonal antibodies, theophylline.

    Time frame: At 6 months

  17. Number of patients with at least 1 other asthma medication

    Long acting beta 2 agonists, long acting anticholinergics, montelukast, macrolides, Anti IgE monoclonal antibodies, theophylline.

    Time frame: At 12 months

  18. Number of patients with at least 1 other asthma medication

    Long acting beta 2 agonists, long acting anticholinergics, montelukast, macrolides, Anti IgE monoclonal antibodies, theophylline.

    Time frame: At 24 months

  19. Number of patients with at least 1 other asthma medication

    Long acting beta 2 agonists, long acting anticholinergics, montelukast, macrolides, Anti IgE monoclonal antibodies, theophylline.

    Time frame: At 36 months

  20. Number of patients with at least 1 other asthma medication

    Long acting beta 2 agonists, long acting anticholinergics, montelukast, macrolides, Anti IgE monoclonal antibodies, theophylline.

    Time frame: At 60 months

  21. Asthma exacerbations

    Systemic corticosteroids (SC) use or doubling the usual dose or at least 48 hours in SC long term users

    Time frame: 6 months

  22. Asthma exacerbations

    Systemic corticosteroids (SC) use or doubling the usual dose or at least 48 hours in SC long term users

    Time frame: At 12 months

  23. Asthma exacerbations

    Systemic corticosteroids (SC) use or doubling the usual dose or at least 48 hours in SC long term users

    Time frame: At 24 months

  24. Asthma exacerbations

    Systemic corticosteroids (SC) use or doubling the usual dose or at least 48 hours in SC long term users

    Time frame: At 36 months

  25. Asthma exacerbations

    Systemic corticosteroids (SC) use or doubling the usual dose or at least 48 hours in SC long term users

    Time frame: At 60 months

  26. Number of patients reporting suboptimal treatment adherence

    Patient-reported adherence to asthma treatment. Suboptimal treatment is defined as less treatment received than expected.

    Time frame: Through study completion, an average of 5 years

  27. Drug survival rate

    Proportion of patients still exposed to treatment

    Time frame: At 6 month

  28. Drug survival rate

    Proportion of patients still exposed to treatment;

    Time frame: At 12 months

  29. Time to drug discontinuation

    Median time between the start of treatment and its definitive cessation

    Time frame: Reported at 6 month

  30. Time to drug discontinuation

    Median time between the start of treatment and its definitive cessation.

    Time frame: Reported at 12 month

  31. Asthma control test (ACT)

    Patient-reported asthma symptoms and control will be collected via the ACT questionnaire; a 5 item, self-administered survey that is designed to help the patient describe their asthma and how it affects their daily activities. ACT questionnaire is a 5-point scale (for symptoms and activities: 1=all the time to 5= not at all; for asthma control rating: 1=not controlled at all to 5=completely controlled).

    Time frame: At 6 months

  32. Asthma control test (ACT)

    Patient-reported asthma symptoms and control will be collected via the ACT questionnaire; a 5 item, self-administered survey that is designed to help the patient describe their asthma and how it affects their daily activities. ACT questionnaire is a 5-point scale (for symptoms and activities: 1=all the time to 5= not at all; for asthma control rating: 1=not controlled at all to 5=completely controlled).

    Time frame: At 12 months

  33. Asthma control test (ACT)

    Patient-reported asthma symptoms and control will be collected via the ACT questionnaire; a 5 item, self-administered survey that is designed to help the patient describe their asthma and how it affects their daily activities. ACT questionnaire is a 5-point scale (for symptoms and activities: 1=all the time to 5= not at all; for asthma control rating: 1=not controlled at all to 5=completely controlled).

    Time frame: At 24 months

  34. Asthma control test (ACT)

    Patient-reported asthma symptoms and control will be collected via the ACT questionnaire; a 5 item, self-administered survey that is designed to help the patient describe their asthma and how it affects their daily activities. ACT questionnaire is a 5-point scale (for symptoms and activities: 1=all the time to 5= not at all; for asthma control rating: 1=not controlled at all to 5=completely controlled).

    Time frame: At 36 months

  35. Asthma control test (ACT)

    Patient-reported asthma symptoms and control will be collected via the ACT questionnaire; a 5 item, self-administered survey that is designed to help the patient describe their asthma and how it affects their daily activities. ACT questionnaire is a 5-point scale (for symptoms and activities: 1=all the time to 5= not at all; for asthma control rating: 1=not controlled at all to 5=completely controlled).

    Time frame: At 60 months

  36. Number of patients with at least 1 sick leaves due to asthma

    Patient-reported sick leaves.

    Time frame: At 6 months

  37. Number of sick leaves due to asthma

    Patient-reported sick leaves.

    Time frame: At 6 months

  38. Number of patients with at least 1 sick leaves due to asthma

    Patient-reported sick leaves.

    Time frame: At 12 months

  39. Number of sick leaves due to asthma

    Patient-reported sick leaves.

    Time frame: At 12 months

  40. Number of patients with at least 1 sick leaves due to asthma

    Patient-reported sick leaves.

    Time frame: At 24 months

  41. Number of sick leaves due to asthma

    Patient-reported sick leaves.

    Time frame: At 24 months

  42. Number of patients with at least 1 sick leaves due to asthma

    Patient-reported sick leaves.

    Time frame: At 36 months

  43. Number of sick leaves due to asthma

    Patient-reported sick leaves.

    Time frame: At 36 months

  44. Number of patients with at least 1 sick leaves due to asthma

    Patient-reported sick leaves.

    Time frame: At 60 months

  45. Number of sick leaves due to asthma

    Patient-reported sick leaves.

    Time frame: At 60 months

  46. St. George's Respiratory Questionnaire (SGRQ)

    The St. George's Respiratory Questionnaire (SGRQ) is a self-reporting questionnaire validated for evaluating quality of life in asthma. The total score is expressed as a percentage, from 0%, no impairment of life quality, to 100%, maximal impairment.

    Time frame: At 6 months

  47. St. George's Respiratory Questionnaire (SGRQ)

    The St. George's Respiratory Questionnaire (SGRQ) is a self-reporting questionnaire validated for evaluating quality of life in asthma. The total score is expressed as a percentage, from 0%, no impairment of life quality, to 100%, maximal impairment.

    Time frame: At 12 months

  48. St. George's Respiratory Questionnaire (SGRQ)

    The St. George's Respiratory Questionnaire (SGRQ) is a self-reporting questionnaire validated for evaluating quality of life in asthma. The total score is expressed as a percentage, from 0%, no impairment of life quality, to 100%, maximal impairment.

    Time frame: At 24 months

  49. St. George's Respiratory Questionnaire (SGRQ)

    The St. George's Respiratory Questionnaire (SGRQ) is a self-reporting questionnaire validated for evaluating quality of life in asthma. The total score is expressed as a percentage, from 0%, no impairment of life quality, to 100%, maximal impairment.

    Time frame: At 36 months

  50. St. George's Respiratory Questionnaire (SGRQ)

    The St. George's Respiratory Questionnaire (SGRQ) is a self-reporting questionnaire validated for evaluating quality of life in asthma. The total score is expressed as a percentage, from 0%, no impairment of life quality, to 100%, maximal impairment.

    Time frame: At 60 months

  51. Asthma Quality of Life Questionnaire (AQLQ) overall score by Visit

    The AQLQ is a 32-item disease-specific questionnaire that has been designed to measure the functional impairments that are most troublesome to adults with asthma. Patients are asked to recall their experiences during the previous 2 weeks and to score each item on a 7-point scale. The overall AQLQ score is the mean response to all 32 questions.

    Time frame: At 6 months

  52. Asthma Quality of Life Questionnaire (AQLQ) overall score by Visit

    The AQLQ is a 32-item disease-specific questionnaire that has been designed to measure the functional impairments that are most troublesome to adults with asthma. Patients are asked to recall their experiences during the previous 2 weeks and to score each item on a 7-point scale. The overall AQLQ score is the mean response to all 32 questions.

    Time frame: At 12 months

  53. Asthma Quality of Life Questionnaire (AQLQ) overall score by Visit

    The AQLQ is a 32-item disease-specific questionnaire that has been designed to measure the functional impairments that are most troublesome to adults with asthma. Patients are asked to recall their experiences during the previous 2 weeks and to score each item on a 7-point scale. The overall AQLQ score is the mean response to all 32 questions.

    Time frame: At 24 months

  54. Asthma Quality of Life Questionnaire (AQLQ) overall score by Visit

    The AQLQ is a 32-item disease-specific questionnaire that has been designed to measure the functional impairments that are most troublesome to adults with asthma. Patients are asked to recall their experiences during the previous 2 weeks and to score each item on a 7-point scale. The overall AQLQ score is the mean response to all 32 questions.

    Time frame: At 36 months

  55. Asthma Quality of Life Questionnaire (AQLQ) overall score by Visit

    The AQLQ is a 32-item disease-specific questionnaire that has been designed to measure the functional impairments that are most troublesome to adults with asthma. Patients are asked to recall their experiences during the previous 2 weeks and to score each item on a 7-point scale. The overall AQLQ score is the mean response to all 32 questions.

    Time frame: At 60 months

  56. EuroQual 5-Dimension Health Status Questionnaire (EQ-5D) index score and health state assessment

    EQ-5D is a standardized instrument for measuring generic health status. The EQ-5D questionnaire has two components: health state description and evaluation. In the description part, health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Mobility dimension asks about the person's walking ability. Self-care dimension asks about the ability to wash or dress by oneself, and usual activities dimension measures performance in "work, study, housework, family or leisure activities". Pain/discomfort dimension asks how much pain or discomfort the person has, and anxiety/depression dimension asks how anxious or depressed the person is. The respondents self-rate their level of severity for each dimension using three-level (EQ-5D-3L) scale. In the evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS).

    Time frame: At 6 months

  57. EuroQual 5-Dimension Health Status Questionnaire (EQ-5D) index score and health state assessment

    EQ-5D is a standardized instrument for measuring generic health status. The EQ-5D questionnaire has two components: health state description and evaluation. In the description part, health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Mobility dimension asks about the person's walking ability. Self-care dimension asks about the ability to wash or dress by oneself, and usual activities dimension measures performance in "work, study, housework, family or leisure activities". Pain/discomfort dimension asks how much pain or discomfort the person has, and anxiety/depression dimension asks how anxious or depressed the person is. The respondents self-rate their level of severity for each dimension using three-level (EQ-5D-3L) scale. In the evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS).

    Time frame: At 12 months

  58. EuroQual 5-Dimension Health Status Questionnaire (EQ-5D) index score and health state assessment

    EQ-5D is a standardized instrument for measuring generic health status. The EQ-5D questionnaire has two components: health state description and evaluation. In the description part, health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Mobility dimension asks about the person's walking ability. Self-care dimension asks about the ability to wash or dress by oneself, and usual activities dimension measures performance in "work, study, housework, family or leisure activities". Pain/discomfort dimension asks how much pain or discomfort the person has, and anxiety/depression dimension asks how anxious or depressed the person is. The respondents self-rate their level of severity for each dimension using three-level (EQ-5D-3L) scale. In the evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS).

    Time frame: At 24 months

  59. EuroQual 5-Dimension Health Status Questionnaire (EQ-5D) index score and health state assessment

    EQ-5D is a standardized instrument for measuring generic health status. The EQ-5D questionnaire has two components: health state description and evaluation. In the description part, health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Mobility dimension asks about the person's walking ability. Self-care dimension asks about the ability to wash or dress by oneself, and usual activities dimension measures performance in "work, study, housework, family or leisure activities". Pain/discomfort dimension asks how much pain or discomfort the person has, and anxiety/depression dimension asks how anxious or depressed the person is. The respondents self-rate their level of severity for each dimension using three-level (EQ-5D-3L) scale. In the evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS).

    Time frame: At 36 months

  60. EuroQual 5-Dimension Health Status Questionnaire (EQ-5D) index score and health state assessment

    EQ-5D is a standardized instrument for measuring generic health status. The EQ-5D questionnaire has two components: health state description and evaluation. In the description part, health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Mobility dimension asks about the person's walking ability. Self-care dimension asks about the ability to wash or dress by oneself, and usual activities dimension measures performance in "work, study, housework, family or leisure activities". Pain/discomfort dimension asks how much pain or discomfort the person has, and anxiety/depression dimension asks how anxious or depressed the person is. The respondents self-rate their level of severity for each dimension using three-level (EQ-5D-3L) scale. In the evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS).

    Time frame: At 60 months

  61. Hospital Anxiety and Depression scale

    The HADS is a fourteen item scale that generates ordinal data. Seven of the items relate to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.

    Time frame: At 6 months

  62. Hospital Anxiety and Depression scale

    The HADS is a fourteen item scale that generates ordinal data. Seven of the items relate to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.

    Time frame: At 12 months

  63. Hospital Anxiety and Depression scale

    The HADS is a fourteen item scale that generates ordinal data. Seven of the items relate to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.

    Time frame: At 24 months

  64. Hospital Anxiety and Depression scale

    The HADS is a fourteen item scale that generates ordinal data. Seven of the items relate to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.

    Time frame: At 36 months

  65. Hospital Anxiety and Depression scale

    The HADS is a fourteen item scale that generates ordinal data. Seven of the items relate to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.

    Time frame: At 60 months

  66. Long term adverse Events associated with corticosteroid therapy.

    Frequency of relevant medical events such as osteoporosis, diabetes, cardiovascular disease.

    Time frame: 60 months

  67. Asthma-related comorbidities

    Prevalence of comorbidities such as rhinosinusitis, obesity, gastroesophageal reflux, sleep obstructive apnea syndrome, ...

    Time frame: At 6 months

  68. Asthma-related comorbidities

    Prevalence of comorbidities such as rhinosinusitis, obesity, gastroesophageal reflux, sleep obstructive apnea syndrome, ...

    Time frame: At 12 months

  69. Asthma-related comorbidities

    Prevalence of comorbidities such as rhinosinusitis, obesity, gastroesophageal reflux, sleep obstructive apnea syndrome, ...

    Time frame: At 24 months

  70. Asthma-related comorbidities

    Prevalence of comorbidities such as rhinosinusitis, obesity, gastroesophageal reflux, sleep obstructive apnea syndrome, ...

    Time frame: At 36 months

  71. Asthma-related comorbidities

    Prevalence of comorbidities such as rhinosinusitis, obesity, gastroesophageal reflux, sleep obstructive apnea syndrome, ...

    Time frame: At 60 months

  72. Death and cause of death

    Time frame: At 6 months

  73. Death and cause of death

    Time frame: At 12 months

  74. Death and cause of death

    Time frame: At 24 months

  75. Death and cause of death

    Time frame: At 36 months

  76. Death and cause of death

    Time frame: At 60 months

  77. Post-procedural adverse Events associated with bronchial thermoplasty

    Frequency of post-procedure medical events such as hemoptysis, respiratory symptoms, asthma, prolonged hospitalization

    Time frame: Up to 24 hours following the procedure

  78. Post-procedural adverse Events associated with bronchial thermoplasty

    Frequency of post-procedure medical events such as hemoptysis, respiratory symptoms, asthma, prolonged hospitalization.

    Time frame: From 24 hours to 1 month following the procedure

  79. Long term adverse events associated with bronchial thermoplasty

    Frequency of long term medical events such as bronchial stenosis.

    Time frame: 60 months

  80. Events of special interest

    Frequency of special interest events including new onset malignancy, severe infection, anaphylaxis.

    Time frame: From treatment initiation to 3 months following treatment initiation

  81. Events of special interest

    Frequency of special interest events including new onset malignancy, severe infection, anaphylaxis.

    Time frame: From 3 months to 12 months following treatment initiation

  82. Events of special interest

    Frequency of special interest events including new onset malignancy, severe infection, anaphylaxis.

    Time frame: From 3 to 5 years following treatment initiation

  83. Blood eosinophil count

    Time frame: At baseline

  84. Total immunoglobulin E (IgE)

    Time frame: At baseline

  85. Chest computed tomography scan

    Dates and description of major findings.

    Time frame: At baseline

  86. Forced Vital Capacity (FVC)

    Time frame: At baseline

  87. Forced Vital Capacity (FVC)

    Time frame: At 6 months

  88. Forced Vital Capacity (FVC)

    Time frame: At 12 months

  89. Forced Vital Capacity (FVC)

    Time frame: At 24 months

  90. Forced Vital Capacity (FVC)

    Time frame: At 36 months

  91. Forced Vital Capacity (FVC)

    Time frame: At 60 months

  92. Forced Expiratory Volume in 1 second (FEV1)

    Time frame: At 6 months

  93. Forced Expiratory Volume in 1 second (FEV1)

    Time frame: At 12 months

  94. Forced Expiratory Volume in 1 second (FEV1)

    Time frame: At 24 months

  95. Forced Expiratory Volume in 1 second (FEV1)

    Time frame: At 36 months

  96. Forced Expiratory Volume in 1 second (FEV1)

    Time frame: At 60 months

  97. FEV1/FVC ratio

    Time frame: At baseline

  98. FEV1/FVC ratio

    Time frame: At 6 months

  99. FEV1/FVC ratio

    Time frame: At 12 months

  100. FEV1/FVC ratio

    Time frame: At 24 months

  101. FEV1/FVC ratio

    Time frame: At 36 months

  102. FEV1/FVC ratio

    Time frame: At 60 months

  103. RV/TLC ratio

    Time frame: At baseline

  104. RV/TLC ratio

    Time frame: At 6 months

  105. RV/TLC ratio

    Time frame: At 12 months

  106. RV/TLC ratio

    Time frame: At 24 months

  107. RV/TLC ratio

    Time frame: At 36 months

  108. RV/TLC ratio

    Time frame: At 60 months

  109. Fractional exhaled nitric oxide (FENO)

    Time frame: At baseline

  110. Costs of severe asthma management

    Total amount of money, expressed in euros, reimbursed by Social Security ( for treatments, medical visits, radiological or laboratory examinations).

    Time frame: Through study completion, an average of 5 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2019 (actual). Primary completion is estimated for Sep 2024, 60 months after the start.

Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 60 months is above that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2019
First posted
Sep 4, 2019
StartActual
Sep 10, 2019
Primary completionEst.
Sep 2024
CompletionEst.
Sep 2025
Last update
Jan 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04077528
Responsible party
Sponsor
First posted
Sep 4, 2019
Start date
Sep 10, 2019
Primary completion
Sep 2024 (estimated)
Completion
Sep 2025 (estimated)
Last update
Jan 18, 2024

Study contacts

Camille TAILLE, MD,PHD
Contact
camille.taille@aphp.fr
01 40 25 68 63
Candice ESTELLAT, Dr
Contact
candice.estellat@aphp.fr
01 42 16 75 72
Camille TAILLE, MD,PHD
study chair · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion